Farida Ahangari,Christine Becker,Daniel G Foster,Maurizio Chioccioli,Meghan Nelson,Keriann Beke,Xing Wang,Aurelien Justet,Taylor Adams,Benjamin Readhead,Carly Meador,Kelly Correll,Loukia N Lili,Helen M Roybal,Kadi-Ann Rose,Shuizi Ding,Thomas Barnthaler,Natalie Briones,Giuseppe DeIuliis,Jonas C Schupp,Qin Li,Norihito Omote,Yael Aschner,Lokesh Sharma,Katrina W Kopf,Björn Magnusson,Ryan Hicks,Anna Backmark,Charles S Dela Cruz,Ivan Rosas,Leslie P Cousens,Joel T Dudley,Naftali Kaminski,Gregory P Downey

Abstract:Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal disorder. Two U.S. Food and Drug Administration-approved antifibrotic drugs, nintedanib and pirfenidone, slow the rate of decline in lung function, but responses are variable and side effects are common. Objectives: Using an in silico data-driven approach, we identified a robust connection between the transcriptomic perturbations in IPF disease and those induced by saracatinib, a selective Src kinase inhibitor originally developed for oncological indications. Based on these observations, we hypothesized that saracatinib would be effective at attenuating pulmonary fibrosis. Methods: We investigated the antifibrotic efficacy of saracatinib relative to nintedanib and pirfenidone in three preclinical models: 1) in vitro in normal human lung fibroblasts; 2) in vivo in bleomycin and recombinant Ad-TGF-β (adenovirus transforming growth factor-β) murine models of pulmonary fibrosis; and 3) ex vivo in mice and human precision-cut lung slices from these two murine models as well as patients with IPF and healthy donors. Measurements and Main Results: In each model, the effectiveness of saracatinib in blocking fibrogenic responses was equal or superior to nintedanib and pirfenidone. Transcriptomic analyses of TGF-β-stimulated normal human lung fibroblasts identified specific gene sets associated with fibrosis, including epithelial-mesenchymal transition, TGF-β, and WNT signaling that was uniquely altered by saracatinib. Transcriptomic analysis of whole-lung extracts from the two animal models of pulmonary fibrosis revealed that saracatinib reverted many fibrogenic pathways, including epithelial-mesenchymal transition, immune responses, and extracellular matrix organization. Amelioration of fibrosis and inflammatory cascades in human precision-cut lung slices confirmed the potential therapeutic efficacy of saracatinib in human lung fibrosis. Conclusions: These studies identify novel Src-dependent fibrogenic pathways and support the study of the therapeutic effectiveness of saracatinib in IPF treatment.

Targeting Src Family Kinase Member Fyn by Saracatinib Attenuated Liver Fibrosis in Vitro and in Vivo.

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

Src Inhibition Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation and Decreasing Connective Tissue Growth Factor

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis

Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver Fibrosis.

SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells via inhibition of cyclin dependent kinase 9

Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis

Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis

Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury.

Sarcoma protein kinase inhibition alleviates liver fibrosis by promoting hepatic stellate cells ferroptosis

Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway

Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk/Hif1α and remodeling liver inflammatory environment

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice

Targeting SYK signaling in myeloid cells protects against liver fibrosis and hepatocarcinogenesis

Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases

Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF‐1α/SLC7A11 pathway

Sphingosine Kinase 2 Cooperating with Fyn Promotes Kidney Fibroblast Activation and Fibrosis Via STAT3 and AKT.

Fibroblast growth factor 18 attenuates liver fibrosis and HSCs activation via the SMO-LATS1-YAP pathway

STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib

Enhancement of Zyxin Promotes Skin Fibrosis by Regulating FAK/PI3K/AKT and TGF-13 Signaling Pathways via Integrins

Enhancement of Zyxin Promotes Skin Fibrosis by Regulating FAK/PI3K/AKT and TGF-β Signaling Pathways via Integrins